Biomedical Research

Purpose: To study the effects of de-escalation antibiotic therapy on clinical cure rate, adverse reaction, and endotracheal intubation rate of severe pneumonia patients.

Methods: A total of 92 severe pneumonia patients who visited doctors in our hospital from January 2015 to January 2016 were randomly selected, and they were randomly divided into observation group (n=46) and control group (n=46). Patients in control group were given escalation antibiotic therapy, whereas those in observation group were given with de-escalation antibiotic therapy. Then, clinical efficacies of the two groups were compared.

Results: Clinical efficacy of patients in the observation group was significantly superior to that of control group (P<0.05). The occurrence rate of adverse reactions of patients in the observation group was significantly lower than that in the control group (P<0.05). Furthermore, both endotracheal incubation and death rates of patients in the observation group were significantly lower than those in the control group (P<0.05).

Conclusion: De-escalation antibiotic therapy for severe pneumonia patients could significantly improve clinical cure rate of patients, lower endotracheal incubation rate, and effectively shorten length of stay and duration of antibiotic use. Moreover, occurrence rate of adverse reactions decreased. Thus, this therapy was safe and reliable and worthy of clinical promotion.

Author(s): Long-Jun Mao, Ping Zhang, Xiao-Yu He
Abstract | Full-Text | PDF

Share this